Phase 3
Completed N=515
Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis
Hyperparathyroidism, Secondary
Source: ClinicalTrials.gov NCT01788046 ↗
Enrolled (actual)
515
Serious AEs
26.0%
Results posted
Mar 2017
Primary outcomePrimary: Percentage of Participants With > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment Phase — 9.6; 75.3 percentage of participants — p=< 0.001
◆ Published Evidence
Highly cited
▲ Trending
154citations · ~17 / year
Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.
Summary
This study is designed to assess the efficacy and safety of etelcalcetide (AMG 416) compared with placebo in the treatment of SHPT in CKD patients receiving hemodialysis.
Linked Publications
-
Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants With > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment Phase |
9.6; 75.3 | < 0.001 sig |
| SECONDARY Percentage of Participants With Mean Predialysis Parathyroid Hormone ≤ 300 pg/mL During the Efficacy Assessment Phase |
4.6; 53.3 | < 0.001 sig |
| SECONDARY Percent Change From Baseline in Predialysis PTH During the Efficacy Assessment Phase |
13.72; -57.39 | < 0.001 sig |
| SECONDARY Percent Change From Baseline in Predialysis Corrected Calcium During the Efficacy Assessment Phase |
0.58; -6.69 | < 0.001 sig |
| SECONDARY Percent Change From Baseline in Predialysis Corrected Calcium Phosphorus Product (cCa x P) During the Efficacy Assessment Phase |
-1.06; -15.84 | < 0.001 sig |
| SECONDARY Percent Change From Baseline in Predialysis Phosphorus During the Efficacy Assessment Phase |
-1.60; -9.63 | < 0.001 sig |
Eligibility Criteria
Inclusion Criteria
- Subject understands the study procedures and agrees to participate in the study by giving written informed consent.
- Subject is 18 years of age or older.
- Subject agrees to not participate in another study of an investigational agent during the study.
- Subject must be receiving hemodialysis 3 times weekly for at least 3 months
- Other Inclusion Criteria may apply
Exclusion Criteria
- Currently receiving treatment in another investigational device or drug study, or ended treatment on another investigational device or drug study(s) within 8 weeks prior to screening.
- Other investigational procedures while participating in this study are excluded.
- Anticipated or scheduled parathyroidectomy during the study period.
- Subject has received a parathyroidectomy within 3 months prior to dosing.
- Anticipated or scheduled kidney transplant during the study period.
- Subject has known sensitivity to any of the products or components to be administered during dosing.
- Subject has participated in a prior clinical trial of AMG 416
- Subject has an unstable medical condition based on medical history, physical examination, and routine laboratory tests, or is otherwise unstable in the judgment of the Investigator.
- Subject has a history of any illness that, in the opinion of the Investigator, might confound the results of the study or pose additional risk to the subject.
- Other Exclusion Criteria may apply
Data sourced from ClinicalTrials.gov (NCT01788046) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.